In a study (Xue, 2020), the main mechanism underlying the resistance of cancer cells to KRAS mutant inhibitors was investigated, and KRAS was found to function in both activated and inactivated states, whereas inhibitors were found to act only on inactivated KRAS. The gene discussed is KRAS; the disease is cancer.